Author + information
- Received August 20, 2019
- Revision received December 3, 2019
- Accepted December 3, 2019
- Published online March 23, 2020.
- Mossab Y. Saeed, MDa,
- David Van Story, BEa,
- Christopher J. Payne, PhDa,b,c,
- Isaac Wamala, MDa,
- Borami Shin, MDa,
- Daniel Bautista-Salinas, MSca,d,
- David Zurakowski, PhDe,
- Pedro J. del Nido, MDa,
- Conor J. Walsh, PhDb,c and
- Nikolay V. Vasilyev, MDa,∗ ()
- aDepartment of Cardiac Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
- bWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts
- cJohn A. Paulson Harvard School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts
- dSchool of Industrial Engineering, Technical University of Cartagena, Cartagena, Spain
- eDepartment of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Nikolay V. Vasilyev, Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115.
• LVSD is associated with reduced LV systolic function and geometrical changes.
• MVR results from LVSD.
• Current management strategies address LVSD and secondary MVR separately, even in advanced stages of LVSD.
• We describe an implantable soft robotic device that would provide a new paradigm in supporting patients with coexistence of LVSD and concomitant MVR by dynamically augmenting native LV contraction and supporting the mitral valve apparatus to eliminate the associated MVR.
Left ventricular failure is strongly associated with secondary mitral valve regurgitation. Implantable soft robotic devices are an emerging technology that enables augmentation of a native function of a target tissue. We demonstrate the ability of a novel soft robotic ventricular assist device to dynamically augment left ventricular contraction, provide native pulsatile flow, simultaneously reshape the mitral valve apparatus, and eliminate the associated regurgitation in an Short-term large animal model of acute left ventricular systolic dysfunction.
This work was supported in part by the U.S. Department of Defense Congressionally Directed Medical Research Programs Discovery Award W81XWH-15-1-0248 (to Dr. Vasilyev), the Wyss Institute for Biologically Inspired Engineering, and the Harvard John A. Paulson School of Engineering and Applied Sciences. Drs. Payne and Vasilyev were the inventors and are listed on a patent application related to the research presented in this paper submitted on June 24, 2016, application number 62/354,196. Dr. Vasilyev is currently an employee of Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received August 20, 2019.
- Revision received December 3, 2019.
- Accepted December 3, 2019.
- 2020 The Authors